Novo Nordisk To 'Double Obesity Drug Sales by 2025'
Danish Group Says Year Off To ‘Good Start’
Executive Summary
Novo Nordisk at its Q1 update lifted full-year guidance and voiced confidence it can double sales of innovative treatments for obesity by 2025.
You may also be interested in...
Novo’s H1 Exceeds Estimates On GLP-1, Obesity Sales Performance
The company’s semaglutide franchise pushed net sales for the first half of 2021 up 5% year over year at DKK66.8bn ($10.6bn), helped by double- and triple-digit growth for Ozempic and Rybelsus.
Novo Nordisk Looks To Broaden Therapeutic Reach With Move Into ATTR
The deal leaves PRX004 in the capable hands of Novo Nordisk, which is hoping to expand beyond obesity and diabetes, while Prothena can focus on the rest of its pipeline.
Novo Nordisk Hopes To Gradually Build US Access To Obesity Therapy
With US FDA approval of Wegovy for obesity, Novo Nordisk prices the weekly injectable at par with its other obesity brand Saxenda. Ramping up sales will require patient, clinician and payer education, the company says.